首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126424

居家傳染病檢查市場－策略分析與預測（2026-2035）

At-Home Infectious Disease Testing Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月11日 | 出版商:

Knowledge Sourcing Intelligence | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

家庭傳染病檢查市場預計將以 9.5% 的複合年成長率成長，從 2026 年的 47.8 億美元成長到 2035 年的 108.5 億美元。

全球居家傳染病檢查市場正經歷強勁成長，這主要得益於消費者對便利、分散式醫療保健日益成長的偏好以及快速診斷技術的顯著進步。該市場是分散式醫療保健的關鍵組成部分，能夠實現疾病的早期發現，並減輕醫院、診所和診斷檢查室的負擔。隨著醫療保健系統鼓勵進行社區疾病監測，以及消費者越來越習慣使用居家診斷技術進行日常健康管理，市場需求不斷成長。集中式檢查室檢測面臨物流方面的限制，疫情期間因運輸延誤和醫療資源有限，往往導致反應時間延長。診斷相關企業正在推出簡化的檢體採集設備、基於智慧型手機的結果解讀以及與遠端醫療的整合，從而改善用戶體驗，並擴大及時獲得感染疾病診斷的途徑。該市場透過在傳統臨床環境之外快速識別感染疾病，增強了公共衛生韌性。由於感染疾病檢測結果直接影響治療策略、隔離措施和疾病監測計劃，因此法律規範、分析準確性、消費者信心和數位醫療保健整合仍然至關重要。

市場促進因素

對分散式醫療服務的需求日益成長

隨著患者擴大尋求減少對醫院和診所依賴的診斷服務，分散式醫療保健加強了感染疾病控制。消費者傾向於選擇快速且方便的居家檢測，以最大限度地減少旅行、等待時間和不必要的接觸感染疾病環境，因此對分散式醫療保健的需求不斷成長。在感染疾病爆發期間，集中式診斷系統面臨營運壓力，因為檢查室容量和預約安排會變得緊張。醫療保健相關企業正在擴展其居家診斷服務、遠端醫療連接和數位報告平台，以提高服務可近性並支援遠距臨床決策。分散式診斷透過將檢測能力分散到各個社區，增強了醫療保健的韌性。

快速分子診斷技術進步

快速分子診斷憑藉其高靈敏度技術，能夠以檢查室級的性能早期識別病原體，從而提高感染疾病檢測的準確性。隨著醫療服務提供者和消費者逐漸認知到精準的居家分子檢測在感染疾病和性行為感染感染方面的臨床價值，市場需求日益成長。雖然傳統的抗原檢測能夠更快地提供結果，但由於感染過程中病毒量波動，其對某些病原體的分析靈敏度可能較低。製造商正在開發小型核酸擴增系統、簡化的工作流程和自動化的結果解讀系統，以提高易用性並促進居家檢測的普及。技術創新正在增強人們對居家傳染病檢查在各種臨床應用中的信心。

數位健康和遠端醫療整合的擴展

隨著診斷結果擴大支持即時線上諮詢和治療建議，數位化醫療平台正在提升居家診斷的價值。消費者期望將自我檢測、電子健康記錄和遠端醫療服務無縫整合，因此市場需求不斷成長。獨立的診斷測試在臨床連續性方面存在局限性，因為醫療服務提供者需要及時獲取患者產生的健康資訊才能做出明智的醫療決策。診斷相關企業正透過整合安全的雲端報告系統、智慧型手機應用程式和遠端醫療夥伴關係，改善溝通並增強醫療服務的連續性。這種互聯互通的數位生態系統促進了居家傳染病檢查服務的長期應用。

加強應對未來感染疾病爆發的準備工作

隨著新興感染疾病持續挑戰全球醫療衛生系統，公共衛生緊急準備仍然是一項策略重點。各國政府、醫療機構和消費者都在透過便利的居家檢測方案來增強應對未來疫情的診斷能力，因此對相關檢測的需求也不斷成長。傳統的疫情應對措施嚴重依賴集中式檢測基礎設施，因為大規模檢測往往會對現有的醫療衛生系統造成巨大壓力。製造商正在擴大多參數呼吸道病原體檢測、提升可擴展的生產能力並採用快速部署策略，這些措施既支持常規疾病監測，又能提高緊急準備能力。長期緊急準備將推動持續的需求，而不僅限於與短期疫情相關的檢查週期。

市場限制因素

使用者檢體採集方法的差異可能會降低非臨床環境下的診斷準確性。家用感染疾病診斷產品的法規核准要求會增加產品開發時間和商業化成本。消費者對正確解讀陽性和陰性結果的認知不足可能會影響臨床決策的準確性。

按測試類型
- 新冠病毒檢測
- 流感檢測
- 愛滋病毒檢測
- 性行為感染（STI）檢測
- 肝炎檢測
- 呼吸道融合細胞病毒（RSV）檢測
- 其他傳染病檢查
透過技術
- 抗原檢測
- 分子（PCR/NAAT）檢測
- 抗體檢測
- 等溫擴增試驗
透過分銷管道
- 網路藥房
- 零售藥房
- 醫院和診斷網路
- 直接面對消費者（DTC）公司的網站
最終用戶
- 成人
- 兒童
- 老年人

第10章：家庭傳染病檢查市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：家庭傳染病檢查市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
中國
日本
韓國
印度
澳洲
巴西
沙烏地阿拉伯

第12章競爭格局

市佔率分析
策略趨勢
企業合併、商業夥伴關係和合作
產品上市及法規核准

第13章：公司簡介

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Siemens Healthineers AG
Becton, Dickinson and Company（BD）
OraSure Technologies, Inc.
QuidelOrtho Corporation
bioMerieux SA
Hologic, Inc.
Lucira Health（Pfizer Inc.）
Cue Health Inc.
SD Biosensor, Inc.
ACON Laboratories, Inc.
Ellume Limited
Everly Health, Inc.
LetsGetChecked

第14章：家庭傳染病檢查市場：商業預測分析

第15章投資與資金籌措分析

創業投資與私募股權的發展趨勢
政府資助和公共衛生舉措
研發投資趨勢

第16章：未來展望

新的成長機遇
未來科技與市場趨勢

簡介目錄

Product Code: KSI-009144

The At-Home Infectious Disease Testing Market is forecast to grow at a CAGR of 9.5%, reaching USD 10.85 billion in 2035 from USD 4.78 billion in 2026.

The global at-home infectious disease testing market is experiencing robust growth, driven by the increasing consumer preference for convenient, decentralized healthcare and significant technological advancements in rapid diagnostics. This market represents an important segment of decentralized healthcare because self-testing enables faster disease detection while reducing pressure on hospitals, clinics, and diagnostic laboratories. Demand is increasing as healthcare systems encourage community-based disease surveillance and consumers become more comfortable using home diagnostic technologies for routine health monitoring. Centralized laboratory testing creates logistical constraints because transportation delays and healthcare facility capacity frequently extend diagnostic turnaround times during periods of high disease transmission. Diagnostic companies are introducing simplified sample collection devices, smartphone-enabled result interpretation, and telehealth integration that improve user experience while expanding access to timely infectious disease diagnosis. The market strengthens public health resilience by enabling rapid identification of infectious diseases outside conventional clinical environments. Regulatory oversight, analytical accuracy, consumer confidence, and digital healthcare connectivity remain critical because infectious disease results directly influence treatment decisions, isolation measures, and disease surveillance programs.

Market Drivers

Rising Demand for Decentralized Healthcare Delivery

Decentralized healthcare strengthens infectious disease management because patients increasingly seek diagnostic services that reduce dependence on hospitals and outpatient clinics. Demand is increasing as consumers prefer rapid home testing that minimizes travel, waiting times, and unnecessary exposure to infectious environments. Centralized diagnostic systems create operational pressure because laboratory capacity and clinical appointments become constrained during periods of elevated disease transmission. Healthcare companies are expanding home-based diagnostic portfolios, telemedicine connectivity, and digital reporting platforms that improve accessibility while supporting remote clinical decision-making. Decentralized diagnostics strengthen healthcare resilience by distributing testing capacity across community settings.

Technological Advancements in Rapid Molecular Diagnostics

Rapid molecular diagnostics improve infectious disease detection because highly sensitive technologies enable earlier identification of pathogens with laboratory-comparable performance. Demand is increasing as healthcare providers and consumers recognize the clinical value of accurate home-based molecular testing for respiratory and sexually transmitted infections. Conventional antigen tests provide faster results but may demonstrate lower analytical sensitivity for selected pathogens because viral load varies during infection progression. Manufacturers are developing compact nucleic acid amplification systems, simplified workflows, and automated result interpretation that improve usability while supporting broader household adoption. Technological innovation strengthens confidence in at-home infectious disease testing across multiple clinical applications.

Expansion of Digital Health and Telemedicine Integration

Digital healthcare platforms improve the value of home diagnostics because diagnostic results increasingly support immediate virtual medical consultations and treatment recommendations. Demand is increasing as consumers expect seamless integration between self-testing, electronic health records, and telehealth services. Standalone diagnostic tests provide limited clinical continuity because healthcare providers require timely access to patient-generated health information for informed medical decision-making. Diagnostic companies are integrating secure cloud reporting, smartphone applications, and telemedicine partnerships that strengthen communication while improving continuity of care. Connected digital ecosystems increase long-term utilization of home infectious disease testing services.

Increasing Preparedness for Future Infectious Disease Outbreaks

Public health preparedness remains a strategic priority because emerging infectious diseases continue creating healthcare system challenges worldwide. Demand is increasing as governments, healthcare organizations, and consumers strengthen diagnostic readiness for future outbreaks through accessible home testing solutions. Traditional outbreak response depends heavily on centralized laboratory infrastructure because large-scale testing frequently overwhelms existing healthcare capacity. Manufacturers are expanding multiplex respiratory panels, scalable manufacturing capacity, and rapid deployment strategies that improve emergency preparedness while supporting routine disease surveillance. Long-term preparedness strengthens sustained demand beyond temporary outbreak-driven testing cycles.

Market Restraints

Variability in user sample collection techniques may reduce diagnostic accuracy outside supervised clinical environments. Regulatory approval requirements for home-use infectious disease diagnostics increase product development timelines and commercialization costs. Limited consumer awareness regarding appropriate interpretation of positive and negative results may affect responsible clinical decision-making.

Technology and Segment Insights

By Test Type

COVID-19 testing represents the largest segment because it established long-term consumer acceptance of self-administered infectious disease testing. Demand continues shifting toward convenient self-testing as households maintain preparedness for seasonal outbreaks and symptomatic evaluation. Influenza testing is gaining traction for differentiating seasonal respiratory infections. HIV testing and sexually transmitted infection (STI) testing are significant and growing segments, driven by the demand for privacy and convenience. Hepatitis testing and Respiratory Syncytial Virus (RSV) testing represent important applications. Manufacturers are expanding test portfolios and improving digital result reporting.

By Technology

Antigen-based testing represents the most widely adopted technology because it delivers rapid results through simple workflows suitable for home use. Consumers prioritize affordability, convenience, and immediate diagnostic information. Molecular (PCR/NAAT) testing is expanding as technologies become more compact and user-friendly, offering higher sensitivity. Antibody testing supports seroprevalence studies and infection history assessment. Isothermal amplification testing is an emerging technology offering molecular-level accuracy with simpler instrumentation. Manufacturers are improving assay sensitivity, test design, and digital interpretation systems.

By Distribution Channel

Online pharmacies dominate the distribution landscape because digital purchasing provides convenient access without requiring physical retail visits. Demand is increasing as consumers prefer home delivery and integrated digital healthcare experiences. Retail pharmacies remain important for immediate access. Hospital and diagnostic networks facilitate integration with clinical care. Direct-to-consumer company websites are a growing channel, enabling direct brand engagement and subscription models.

Competitive and Strategic Outlook

The competitive landscape features major diagnostic companies and specialized point-of-care testing providers. Abbott Laboratories maintains a leading position through its extensive diagnostic expertise, global manufacturing, and broad portfolio of rapid diagnostic solutions. F. Hoffmann-La Roche Ltd. differentiates itself through advanced molecular diagnostics expertise and integrated digital healthcare solutions. Siemens Healthineers AG leverages its diagnostic technologies and digital health infrastructure to support decentralized infectious disease management. Becton, Dickinson and Company (BD) differentiates itself through expertise in specimen collection and diagnostic instrumentation. OraSure Technologies, Inc. specializes in non-invasive specimen collection and rapid diagnostics. QuidelOrtho Corporation combines rapid diagnostic innovation with expertise in respiratory infectious disease detection. bioMerieux SA specializes in infectious disease diagnostics and microbiology. Hologic, Inc. brings advanced molecular diagnostic technologies and women's health expertise.
Strategic developments include increasing integration of multiplex testing platforms capable of identifying multiple respiratory pathogens, expansion of molecular home-testing technologies, and strengthening of digital health and telemedicine connectivity. Companies are forming partnerships to improve clinical validation and expand distribution. Product launches focus on simplified sample collection, smartphone-enabled result interpretation, and connected reporting. Companies that successfully combine laboratory-quality accuracy, intuitive product design, and secure digital integration are expected to strengthen their competitive positions.

Conclusion

The at-home infectious disease testing market is poised for significant growth, driven by the demand for decentralized healthcare, technological advancements, and increasing public health preparedness. The evolution from emergency pandemic response toward routine, connected, and multiplexed home diagnostics is reshaping the market. Companies that successfully deliver accurate, user-friendly, and digitally integrated testing solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding consumer acceptance will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. At-Home Infectious Disease Testing Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Home Diagnostics Landscape
3.8 Consumer Adoption Analysis
3.9 Point-of-Care & Self-Testing Ecosystem
3.10 Digital Health & Telemedicine Integration
3.11 Public Health Preparedness Landscape

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Advances in Rapid Diagnostic Technologies
6.2 Molecular At-Home Testing
6.3 Artificial Intelligence in Digital Diagnostics
6.4 Smartphone-Based Result Interpretation
6.5 Multiplex Infectious Disease Testing
6.6 Connected Home Diagnostics Platforms
6.7 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Emergency Use & Approval Pathways
7.3 Quality Standards and Compliance

8. At-Home Infectious Disease Testing Market Landscape Analysis

8.1 Analysis by Test Type
8.2 Analysis by Technology
8.3 Analysis by Sample Type
8.4 Analysis by Distribution Channel
8.5 Analysis by End User

9. At-Home Infectious Disease Testing Market Segment Analysis (2021-2035)

9.1 By Test Type
- 9.1.1 COVID-19 Testing
- 9.1.2 Influenza Testing
- 9.1.3 HIV Testing
- 9.1.4 Sexually Transmitted Infection (STI) Testing
- 9.1.5 Hepatitis Testing
- 9.1.6 Respiratory Syncytial Virus (RSV) Testing
- 9.1.7 Other Infectious Disease Tests
9.2 By Technology
- 9.2.1 Antigen-Based Testing
- 9.2.2 Molecular (PCR/NAAT) Testing
- 9.2.3 Antibody Testing
- 9.2.4 Isothermal Amplification Testing
9.3 By Distribution Channel
- 9.3.1 Online Pharmacies
- 9.3.2 Retail Pharmacies
- 9.3.3 Hospital & Diagnostic Networks
- 9.3.4 Direct-to-Consumer Company Websites
9.4 By End User
- 9.4.1 Adults
- 9.4.2 Pediatric Population
- 9.4.3 Geriatric Population